Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osemitamab in CLDN18.2 Positive Biliary Tract Cancer
NCT05190575Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of osemitamab in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Started Jan 2022; status: completed.
02
Drugs
osemitamab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05190575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190575.